Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer
2012-002250-23Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abiraterone, dactolisib and buparlisib in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: Maximum tolerated dose and recommended Phase II dose (BEZ235 or BKM120 in combination with abiraterone acetate). Started Jul 2012; status: suspended.
02
Drugs
abirateronedactolisibbuparlisib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-002250-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002250-23.